EurekAlert! -
11 Mar 2018 07:00
(University of Kentucky) Data presented from a Late-Breaking Clinical Trial at the American College of Cardiology's 67th Annual Scientific Session Data demonstrated the effectiveness of beta blockers or ACE inhibitors to reduce the risk of cardio toxicity for HER2-positive breast cancer patients undergoing chemotherapy
Share this Article